Adults and Pneumonia: What You Need to Know About the Changing Risks
"New research from Japan reveals how childhood vaccinations are impacting adult pneumonia risks, highlighting emerging threats and the importance of adult vaccinations."
Pneumonia poses a significant health threat to adults, especially those over 65 or with underlying health conditions. While effective treatments exist, the bacteria Streptococcus pneumoniae, a major cause of invasive pneumococcal diseases (IPDs), is constantly evolving. This evolution, spurred by factors like antibiotic use and widespread vaccination programs, necessitates continuous monitoring and adaptation of preventative strategies.
In Japan, the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) for children in 2010 marked a turning point in the fight against pneumonia. Subsequent changes in vaccination schedules, including the shift to PCV13, have had a cascading effect on the types of pneumococcal bacteria circulating and their resistance to drugs. Understanding these shifts is critical for protecting adult populations.
Recent research closely examined these changes, analyzing data collected from adult IPD cases in Japan between 2010 and 2013. The findings reveal a complex picture of how childhood vaccination programs are indirectly influencing adult health, with some positive outcomes alongside the emergence of new challenges.
Current Vaccination and Disease Trends
The CDC reports that 25.1% of U.S. adults age 18 and older had ever received a pneumococcal vaccination in 2024. CDC surveillance data also show that invasive pneumococcal disease rates in the United States decreased dramatically after pneumococcal conjugate vaccines were introduced. A 21-month study found that 13.2% of adults, representing 6.8 million people, received a pneumococcal vaccine, with the 20-valent vaccine accounting for most vaccinations at 9.6%.
Current Recommendations and Evidence Limits
CDC recommendations for adult pneumococcal vaccination depend on age, risk conditions, and vaccines received previously. ACIP recommendations specify PCV20 alone or PCV15 followed by PPSV23 for adults age 65 and older and for certain adults age 19 to 64 with underlying conditions or other risk factors who have not received a pneumococcal conjugate vaccine or whose history is unknown. Comparing vaccine-effectiveness results across observational studies remains difficult because populations, study designs, and outcomes vary, while the availability of PCV21 is prompting reconsideration of prevention strategies.
More Than a Century of Vaccine Development
A historical review describes 111 years of pneumococcal vaccination and changing vaccine strategies in adults. The National Vaccine Information Center dates the earliest known U.S. pneumococcal vaccines to 1909, when heat-treated whole-cell vaccines were used. Another account places the earliest forms in the late 1970s, so published histories differ on how the vaccine era should be dated; broader development and use have nonetheless spanned several decades.
The Impact of Childhood Vaccinations on Adult Pneumonia: A Shifting Landscape
The study revealed a notable decrease in the prevalence of PCV7 serotypes among adults with IPDs, dropping from 43.3% to 23.8%. This decline was most significant for serotype 6B, a strain targeted by the vaccine. Similarly, there was a reduction in serotypes covered by the 23-valent pneumococcal polysaccharide vaccine (PPSV23), which is commonly recommended for older adults.
- Decreased PCV7 serotypes: Good news, showing the vaccines are working.
- Rise of non-PPSV23 serotypes: A concerning trend, demanding attention.
- Emergence of drug-resistant strains: Making treatment more difficult.
An Evolving Evidence Base
Recent research on adult pneumococcal vaccination continues to evaluate vaccine effectiveness, immunization strategies, and the changing disease landscape. Reviews may help clarify how newer products fit into prevention, but findings should be interpreted in light of differences in study populations and methods. The evidence is therefore best viewed as evolving rather than as a single final answer.
Limits and Unresolved Questions
Pneumococcal vaccination is not a complete solution to every cause of adult pneumonia. Evidence can be difficult to compare when studies use different populations, designs, and outcomes, and changing vaccine products create additional uncertainty about the best strategy. These limitations support individualized clinical discussion rather than assuming that one approach works equally well for every adult.
Comparing Vaccine Options
Four distinct pneumococcal vaccines are currently available, and they provide protection against different serotypes of Streptococcus pneumoniae. Comparisons have evaluated PCV15 and PCV13, each followed by PPSV23, in healthy adults age 50 and older and in adults age 18 to 49. PCV20, also known as Prevnar 20, and PCV15, also known as Vaxneuvance, were approved in 2021, while ACIP publishes recommendations for their use.
Protecting Yourself: What These Findings Mean for Adults
The Japanese study underscores the dynamic nature of pneumonia-causing bacteria and the indirect yet significant impact of childhood vaccination programs on adult health. While PCV7 and PCV13 vaccines have proven effective in reducing the overall burden of IPDs, the emergence of non-vaccine serotypes and drug-resistant strains requires a proactive approach to adult health.
What the Evidence Shows
A systematic review and meta-analysis examined PCV13 and PPSV23 efficacy or effectiveness against vaccine-type invasive pneumococcal disease and pneumococcal pneumonia in adults. Newer PCV15 and PCV20 vaccines were licensed for U.S. adults on the basis of safety and immunogenicity data compared with PCV13 and PPSV23. Reviews therefore provide a broad picture of the evidence while also emphasizing that vaccine performance depends on the outcome and vaccine type studied.
An Expanding Vaccine Landscape
A 2025 review describes a new era of adult pneumococcal vaccination shaped by disease burden, vaccine evolution, and expanding immunization strategies. Its companion listing likewise frames the field around the question of what comes next for adult vaccination. Future work is likely to focus on how newer products and strategies should be integrated as the vaccine landscape expands.
Implementation Across Populations
Adult pneumococcal prevention must account for differences in age, health conditions, prior vaccination, and access to care. The expanding number of vaccine options can make implementation more complex because recommendations depend on individual history and risk. These system-level challenges may affect how consistently eligible adults receive an appropriate vaccine.
Individual Decisions Matter
For adults, pneumococcal vaccination decisions are shaped by personal age, medical risks, and prior vaccines. Because recommendations vary by these factors, a healthcare provider can help determine which option fits an individual's situation. Real-world protection therefore depends not only on vaccine availability but also on people receiving the recommended product and schedule.
Adults, especially those 65 and older or with underlying health conditions, should discuss vaccination options with their healthcare providers. While PPSV23 offers broad coverage against many pneumococcal serotypes, it may not be effective against the emerging non-vaccine types. The potential benefits of PCV13 for adults should also be considered, particularly for those at higher risk of IPDs.
Continued surveillance and research are crucial for monitoring serotype changes and resistance patterns in S. pneumoniae. This information will inform future vaccine development and public health strategies aimed at minimizing the impact of pneumonia on adult populations worldwide.